Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VELODROME
2020-001313-20Phase 3Active
- Sponsor
- Roche
- Start
- Feb 2021
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of ranibizumab in exudative macular degeneration (2 arms), sponsored by Roche. Primary endpoint: Change from baseline in best-corrected visual acuity averaged over Weeks 68 and 72. Started Feb 2021; status: active.
02
Drugs
ranibizumab
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on 2020-001313-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001313-20.